- Home
- BPTH vs SEEL Comparison
BPTH vs SEEL Comparison
Compare BPTH & SEEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- SEEL
- Stock Information
- Founded
- BPTH 2007
- SEEL 2016
- Country
- BPTH United States
- SEEL United States
- Employees
- BPTH N/A
- SEEL N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- SEEL Biotechnology: Pharmaceutical Preparations
- Sector
- BPTH Health Care
- SEEL Health Care
- Exchange
- BPTH Nasdaq
- SEEL Nasdaq
- Market Cap
- BPTH 2.2M
- SEEL 1.8M
- IPO Year
- BPTH N/A
- SEEL N/A
- Fundamental
- Price
- BPTH $0.87
- SEEL $3.41
- Analyst Decision
- BPTH Strong Buy
- SEEL
- Analyst Count
- BPTH 2
- SEEL 0
- Target Price
- BPTH $30.00
- SEEL N/A
- AVG Volume (30 Days)
- BPTH 81.3K
- SEEL 1.3M
- Earning Date
- BPTH 11-13-2024
- SEEL 11-12-2024
- Dividend Yield
- BPTH N/A
- SEEL N/A
- EPS Growth
- BPTH N/A
- SEEL N/A
- EPS
- BPTH N/A
- SEEL 47.06
- Revenue
- BPTH N/A
- SEEL $2,013,999.00
- Revenue This Year
- BPTH N/A
- SEEL N/A
- Revenue Next Year
- BPTH N/A
- SEEL $9,366.67
- P/E Ratio
- BPTH N/A
- SEEL $0.07
- Revenue Growth
- BPTH N/A
- SEEL 76.05
- 52 Week Low
- BPTH $0.86
- SEEL $2.77
- 52 Week High
- BPTH $21.60
- SEEL $844.80
- Technical
- Relative Strength Index (RSI)
- BPTH 34.38
- SEEL 44.39
- Support Level
- BPTH $0.86
- SEEL $4.00
- Resistance Level
- BPTH $0.92
- SEEL $8.80
- Average True Range (ATR)
- BPTH 0.06
- SEEL 0.93
- MACD
- BPTH 0.01
- SEEL 0.04
- Stochastic Oscillator
- BPTH 5.79
- SEEL 10.61
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About SEEL Seelos Therapeutics Inc.
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.